<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01546337</url>
  </required_header>
  <id_info>
    <org_study_id>CCTIRS908111</org_study_id>
    <nct_id>NCT01546337</nct_id>
  </id_info>
  <brief_title>Search for Predictive Markers of Efficacy of ESAs in Patients With Non-myeloid Malignancies or Myelodysplastic Syndrome</brief_title>
  <acronym>EPO</acronym>
  <official_title>Search for Predictive Markers of Efficacy of Epoetin Beta (NEORECORMON) in the Treatment of Anemia in Patients With Non-myeloid Malignancies Receiving Chemotherapy or Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anemia is common among cancer patients and the treatment of choice is now
      Erythropoiesis-Stimulating Agents (ESAs). However, some patients do not respond to treatment.
      The purpose of this study is to evaluate the predictive value of endogenous erythropoietin
      rate on the response to erythropoietin beta. First, by confirming the predictive value of
      endogenous erythropoietin observed / predicted ratio on this response. Then if it is
      confirmed by establishing the optimal value of this ratio.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anemia is common among cancer patients and the treatment of choice is now
      Erythropoiesis-Stimulating Agents (ESAs). However, some patients do not respond to treatment.
      Thus, only 50-60% of patients with multiple myeloma or non-Hodgkin lymphoma respond to ESAs.
      The purpose of this study is to evaluate the predictive value of endogenous erythropoietin
      rate on the response to erythropoietin beta. First, by confirming the predictive value of
      endogenous erythropoietin observed / predicted ratio on this response. Then if it is
      confirmed by establishing the optimal value of this ratio.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>response to erythropoietin</measure>
    <time_frame>12 weeks</time_frame>
    <description>Complete response : increase of 2g/dl of erythropoietin rate or stopping of transfusion requirements.
Partial response : increase of 1 to 2g/dl rate of erythropoietin or 50% reduction of transfusion requirements.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>endogenous erythropoietin rate</measure>
    <time_frame>Within 8 days before inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemoglobin rate</measure>
    <time_frame>Weeks 0,4,8 and 12</time_frame>
    <description>Weeks 0 = first ESAs injection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of transfusions during the duration of the study</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Anemia</condition>
  <condition>Hemopathies</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Non-myeloid haemopathy or Myelodysplastic Syndromes patients with anemia, who needs ESAs
        treatment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18

          -  patients with non-myeloid haemopathy receiving chemotherapy or myelodysplastic
             syndrome

          -  indication of ESAs therapy with Hb &lt; 11g/dl

        Exclusion Criteria:

          -  uncontrolled hypertension

          -  anemia due to deficiency

          -  pregnant and lactating women

          -  patient who received treatment with erythropoiesis-activating factors in the two
             months preceding inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Escoffre-Barbe Martine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laviolle Bruno, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laval Hospital</name>
      <address>
        <city>Laval</city>
        <zip>53015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rennes University Hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yves Le Foll Hospital</name>
      <address>
        <city>Saint-Brieuc</city>
        <zip>22027</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Malo Hospital</name>
      <address>
        <city>Saint-Malo</city>
        <zip>35403</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bretagne Atlantic Hospital</name>
      <address>
        <city>Vannes</city>
        <zip>56017</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2012</study_first_submitted>
  <study_first_submitted_qc>March 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2012</study_first_posted>
  <last_update_submitted>March 6, 2012</last_update_submitted>
  <last_update_submitted_qc>March 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anemia</keyword>
  <keyword>non-myeloid haemopathy</keyword>
  <keyword>myelodysplastic syndrome</keyword>
  <keyword>Erythropoiesis stimulating agents</keyword>
  <keyword>predictive markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

